Nanoparticle Delivery of Angiogenic Gene Therapy. Save the Vessels, Save the Lung!

Jarod A. Zepp,Cristina M Alvira,Cristina M. Alvira

DOI: https://doi.org/10.1164/rccm.202004-0933ED

IF: 24.7

2020-07-02

American Journal of Respiratory and Critical Care Medicine

Abstract:Significant growth of the lung occurs after birth during alveolarization, the final stage of lung development that markedly increases the gas exchange surface area ( 1 ). The completion of lung development postnatally renders the immature lung highly susceptibile to injuries that disrupt this final stage of development. This is particularly evident in the context of premature birth in which arrested alveolar and vascular development result in bronchopulmonary dysplasia (BPD), the most common complication of prematurity and significant cause of morbidity and mortality ( 2 ). Evidence suggests that disrupted pulmonary angiogenesis is key to the pathogenesis of BPD. Proangiogenic factors are decreased, and the pulmonary microvasculature is dysmorphic in infants dying from BPD ( 3 ). In experimental models, directly blocking angiogenesis impairs alveolarization and, conversely, enhancing angiogenesis; for example, by augmenting VEGF (vascular endothelial growth factor) signaling, can improve alveolarization in the setting of injury ( 4 ). Therefore, the development of strategies to enhance alveolarization by promoting pulmonary angiogenesis hold great promise as potential therapies to meaningfully impact the incidence and severity of BPD. In this issue of the Journal , Bolte and colleagues (pp. 100–111 ) demonstrate that nanoparticle delivery of the transcription factors Foxf1 and Foxm1 effectively enhances angiogenesis and preserves alveolarization in a murine model of BPD induced by chronic hyperoxia ( 5 ).

respiratory system,critical care medicine